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Fertility and Sterility®Study Question: Can the priorities for future research in infertility be identified?
Summary Answer: The top 10 research priorities for the four areas of male infertility, female and unexplained infertility, medically
assisted reproduction, and ethics, access, and organization of care for people with fertility problems were identified.
What is Known Already: Many fundamental questions regarding the prevention, management, and consequences of infertility remain
unanswered. This is a barrier to improving the care received by those people with fertility problems.
Study Design, Size, Duration: Potential research questions were collated from an initial international survey, a systematic review of
clinical practice guidelines, and Cochrane systematic reviews. A rationalized list of confirmed research uncertainties was prioritized in
an interim international survey. Prioritized research uncertainties were discussed during a consensus development meeting. Using a
formal consensus development method, the modified nominal group technique, diverse stakeholders identified the top 10 research pri-
orities for each of the categories male infertility, female and unexplained infertility, medically assisted reproduction, and ethics, access,
and organization of care.
Participants/Materials, Setting, Methods: Healthcare professionals, people with fertility problems, and others (healthcare funders,
healthcare providers, healthcare regulators, research funding bodies and researchers) were brought together in an open and transparent
process using formal consensus methods advocated by the James Lind Alliance.
Main Results and the Role of Chance: The initial survey was completed by 388 participants from 40 countries, and 423 potential
research questions were submitted. Fourteen clinical practice guidelines and 162 Cochrane systematic reviews identified a further
236 potential research questions. A rationalized list of 231 confirmed research uncertainties were entered into an interim prioritization
survey completed by 317 respondents from 43 countries. The top 10 research priorities for each of the four categories male infertility,
female and unexplained infertility (including age-related infertility, ovarian cysts, uterine cavity abnormalities, and tubal factor
infertility), medically assisted reproduction (including ovarian stimulation, IUI, and IVF), and ethics, access, and organization of
care, were identified during a consensus development meeting involving 41 participants from 11 countries. These research priorities
were diverse and seek answers to questions regarding prevention, treatment, and the longer-term impact of infertility. They
highlight the importance of pursuing research which has often been overlooked, including addressing the emotional and
psychological impact of infertility, improving access to fertility treatment, particularly in lower resource settings, and securing
appropriate regulation. Addressing these priorities will require diverse research methodologies, including laboratory-based science,
qualitative and quantitative research, and population science.
Limitations, Reasons for Caution: We used consensus development methods, which have inherent limitations, including the represen-
tativeness of the participant sample, methodological decisions informed by professional judgement, and arbitrary consensus
definitions.
Wider Implications of the Findings: We anticipate that identified research priorities, developed to specifically highlight themost press-
ing clinical needs as perceived by healthcare professionals, people with fertility problems, and others, will help research funding orga-
nizations and researchers to develop their future research agenda.
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ORIGINAL ARTICLE: INFERTILITYINTRODUCTION
The ultimate aim of infertility research is to improve clinical
practice and optimize the chances of people with fertility
problems achieving parenthood. For this to be possible,
research needs to address questions that are pertinent to peo-
ple with infertility, be conducted using appropriate methods,
and be reported in a comprehensive, transparent, and acces-
sible manner (6). The first step in research production is to
identify appropriate questions. Traditionally, research fund-
ing organizations and researchers have identified, refined,
and prioritized their own research agenda. It is unlikely that
such prioritization has used formal consensus methods,
engaged wider stakeholders, including people with fertility
problems, and was independent of commercial interests.
There has been modest improvement in some countries,
including The Netherlands, UK, and the USA, which has
emphasized the importance of including patients and the pub-
lic in developing research priorities (11).
Sir Iain Chalmers, founder of the Cochrane Collaboration,
has advocated for research priorities to be jointly identified by
healthcare professionals, patients, and communities (4). He
established the James Lind Alliance, which brings together
healthcare professionals, patients, and others, in priority
setting partnerships. Using formal consensus methods, each
priority setting partnership engages in an open and trans-
parent process to identify and prioritize unanswered research
questions, known as research uncertainties, in a particular
area of health care (13). The expectation is that prioritized
research uncertainties will establish the future research
agenda of funding organizations and researchers. As a result,
it is hoped that the gap will close between what research is
needed and what research is pursued (25).
An international collaboration has brought health care
professionals, people with fertility problems, and others
together within a Priority Setting Partnership for Infertility
to develop future research priorities for male infertility, fe-
male and unexplained infertility, medically assisted repro-
duction, and ethics, access, and organization of care.MATERIALS AND METHODS
An international multidisciplinary steering group, including
healthcare professionals, people with fertility problems, and
researchers was established to provide a diverse range of per-
spectives to inform key methodological decisions. The steer-
ing group was convened during the development of the
study protocol, before the launch of the initial survey and
interim prioritization survey, and before the consensus devel-
opment meeting. A systematic review of registered, progress-
ing, and completed priority setting research settings was
completed to assist with the planning and delivery of the
study (11).
Research uncertainties related to infertility associated
with endometriosis, miscarriage, and polycystic ovary syn-
drome were not considered because of other current or
completed research prioritization initiatives (12, 24).
Research priorities were developed in a three-stage pro-
cess using consensus methods advocated by the James Lind
Alliance (13). Potential research uncertainties were gathered182through an online survey of healthcare professionals, people
with fertility problems, and others. Healthcare professionals,
including embryologists, fertility specialists, and gynecolo-
gists, were recruited through the British Fertility Society,
Core Outcomes in Women’s Health (CROWN) initiative, Co-
chrane Gynaecology and Fertility Group, Fertility and Steril-
ity Forum, Reproductive Medicine Clinical Study Group, and
Royal College of Obstetricians and Gynecologists. People with
fertility problems were recruited through Fertility Europe, an
umbrella organization of more than 20 European patient or-
ganizations, including Fertility Network UK and Freya,
Fertility New Zealand, RESOLVE: The National Infertility As-
sociation, and the Women’s Voices Involvement Panel hosted
by the Royal College of Obstetricians and Gynecologists.
Other people could register to participate, including health-
care funders, healthcare regulators, and researchers. Recruit-
ment was supported by an active social media campaign.
Potential participants received an explanatory video abstract,
a plain language summary, and survey instructions. Before
completing the survey, participants provided demographic
details, including age, gender, and geographical location,
and information pertaining to their professional or personal
experience of infertility. Participants were invited to suggest
up to five research questions related to infertility that they
considered unanswered.
After the survey had closed, the survey responses were
examined in detail within an iterative process. Individual re-
sponses were reviewed by at least twomembers of the steering
group. Responses were excluded if they included questions
that did not fit the scope of the study, were not answerable
by research, related to a specific person or situation, or were
ambiguous. Incomplete responses were also excluded. The re-
maining responses were formatted into appropriate research
questions.
In addition, research recommendations were identified
from a systematic review of clinical practice guidelines and
Cochrane systematic reviews. Clinical practice guidelines
relevant to infertility were identified by searching biblio-
graphical databases, including Embase, International Guide-
line Library, and MEDLINE, from 2007 to July 2017.
Research recommendations were extracted verbatim from
clinical practice guidelines. Using a data extraction tool avail-
able to the Cochrane Gynaecology and Fertility Group,
research recommendations were extracted from individual
Cochrane reviews evaluating potential fertility treatments.
Research recommendations from clinical practice guidelines
and Cochrane systematic reviews were reviewed by twomem-
bers of the steering group and formatted into appropriate
research questions. Differences in opinion were resolved by
discussion with the steering group.
The long list of potential research questions was orga-
nized by allocating individual research questions in four cat-
egories: male infertility; female and unexplained infertility,
including age-related infertility, ovarian cysts, uterine cavity
abnormalities, and tubal factor infertility; medically assisted
reproduction including ovarian stimulation, IUI, and IVF;
and ethics, access, and organization of care. These categories
were identified in consultation with the steering group. Dupli-
cate research questions were removed. Research questionsVOL. 115 NO. 1 / JANUARY 2021
Fertility and Sterility®were checked against the published research evidence,
including clinical practice guidelines, Cochrane systematic
reviews, and randomized trials, and those questions consid-
ered to be already answered were removed.
The long list of confirmed research uncertainties was
entered into an interim prioritization survey. Initial survey
participants were invited to participate in the survey. In addi-
tion, healthcare professionals, people with fertility problems,
and others were recruited using the same methods as the
initial survey. Before completing the survey, participants pro-
vided demographic details, including age, gender, and
geographical location, and information pertaining to their
professional or personal experience of infertility. Participants
were invited to select the research uncertainties they consid-
ered most important. After the survey had closed, questions
were ranked based on the frequency they had been chosen
by participants.
The top 15 research uncertainties in each category were
discussed during a consensus development meeting (data
are presented in the Supplementary Table S1). A formal
consensus development method, the modified nominal group
technique, was used to identify the top 10 research uncer-
tainties for each category (13). Healthcare professionals, peo-
ple with fertility problems, and others who had completed the
initial or interim prioritization survey were invited to partic-
ipate. The modified nominal group technique does not depend
on statistical power. In consultation with the steering group,
the aim was to recruit between 15 and 30 participants, as
this number has yielded sufficient results and assured validity
in other settings (18).
Before the consensus development meeting, partici-
pants provided demographic details, including age, gender,
and geographical location, and information pertaining to
their professional or personal experience of infertility.
Following an introductory session, participants were as-
signed to one of two groups, each with a facilitator, to
discuss the ranking of prioritized research uncertainties.
The assignments were pre-specified to ensure a mixture
of healthcare professionals, people with fertility problems,
and others. The groups were provided with a set of cards
with an individual research uncertainty printed on each.
Each participant was asked to contribute their opinions
on the research uncertainties they felt most and least
strongly about. Following this initial discussion, partici-
pants were invited to discuss the ordering of the research
uncertainties. By the end of the session the research un-
certainties were placed in ranked order. The rankings
from the two groups were aggregated into a single
ranking order and presented to the entire group. Partici-
pants were invited to discuss the ordering of the research
uncertainties. By the end of the discussion the research
uncertainties were placed in a final ranked order.
The National Research Ethics Service, UK, advised the
study did not require formal review.RESULTS
The initial survey was completed by 179 healthcare profes-
sionals (46%), 153 people with fertility problems (39%), andVOL. 115 NO. 1 / JANUARY 202156 others (14%), from 40 countries (Table 1). Four hundred
and twenty-three responses were submitted (Fig. 1). Following
review, 136 responses (32%) were excluded. Clinical practice
guidelines relevant to infertility were identified by searching
bibliographical databases; the search strategy identified
3,680 records. After excluding 731 duplicate records, 2,949 ti-
tles and abstracts were screened. Thirty-two potentially rele-
vant clinical practice guidelines were evaluated. Fourteen
clinical practice guidelines met the inclusion criteria,
including two guidelines related to infertility in general
(17, 19), five guidelines related to male infertility (2, 14, 15),
five guidelines related to uterine anomalies (1, 3, 16, 21, 23),
and two guidelines related to medically assisted reproduction
(20, 22). Thirteen research recommendations were extracted
from the clinical practice guidelines. The Cochrane Gynaecol-
ogy and Fertility Group provided research recommendations
from 162 Cochrane systematic reviews. Two hundred and
twenty-three potential research questions were extracted
from these research recommendations. A long list of 533 po-
tential research uncertainties were reviewed, 241 duplicate
research uncertainties were removed and 51 research uncer-
tainties which had been answered by research were also
removed.
A rationalized list of 231 confirmed research uncer-
tainties was developed, which included 34 research uncer-
tainties related to male infertility, 48 research uncertainties
related to female and unexplained infertility, 101 research
uncertainties related to medically assisted reproduction, and
48 research uncertainties related to ethics, access, and organi-
zation of care. These confirmed research uncertainties were
entered into an interim prioritization survey, which was
completed by 143 healthcare professionals, 119 people with
fertility problems, and 55 others, from 43 countries.
Nineteen health care professionals, 14 people with per-
sonal experience of infertility, and eight others, from 11
countries, participated in the consensus development
meeting. The modified nominal group technique was used
to prioritize the top 10 research uncertainties for male infer-
tility, female and unexplained infertility, medically assisted
reproduction, and ethics, access, and organization of care.
Fifteen highly prioritized research uncertainties for each cate-
gory were discussed during the consensus development
meeting (Supplementary Table S1). The 15 highly prioritized
research uncertainties were initially discussed by two separate
groups and at the end of the discussion they ranked the
research uncertainties. The first-round ranking is presented
in Supplementary Table S1. The rankings from the two groups
were aggregated into a single ranking order and discussed by
the entire group (Supplementary Table S1). Participants were
encouraged to discuss and finalize the rank order of the
research priorities. The top 10 research priorities are presented
in Fig. 2.DISCUSSION
The Priority Setting Partnership for infertility has brought
together healthcare professionals, people with fertility prob-
lems, and others to identify the top 10 research priorities for
future infertility research. These research priorities are diverse183
TABLE 1








People with fertility problems 153 119 14
Healthcare professionals 179 143 19
Embryologists 39 26 4
Fertility specialists 71 64 6
Gynaecologists 44 28 6
Others 25 25 3
Researchers 28 28 7
Others 15 10 1
Prefer not to say 13 17 0
Gender, n
Female 223 176 25
Male 129 119 16
Prefer not to say 36 22 0
Age (years), n
Below 30 47 26 2
30 to 39 118 85 12
40 to 49 61 60 5
50 to 59 73 61 13
Over 60 42 29 5
Prefer not to say 47 56 4
Geographical location, n
Africa 15 14 0
Asia 57 34 3
Australia and New Zealand 61 51 22
Europe 115 117 13
North America 82 54 3
South America 27 19 0
Prefer not to say 31 28 0
Duffy. Priorities for future infertility research. Fertil Steril 2020.
ORIGINAL ARTICLE: INFERTILITYand seek answers to questions regarding prevention, treat-
ment, and the longer-term impact, as well as wider contextual
issues related to access and public health policy. They high-
light the importance of pursuing research which has often
been overlooked, including addressing the emotional and
psychological impact of infertility, improving access to
fertility treatment, particularly in lower resource settings,
and securing appropriate regulation. Addressing these prior-
ities will require diverse research methodologies, including
laboratory-based science, qualitative and quantitative
research, and population science.Strengths and Limitations
The James Lind Alliance has published guidance to inform the
design of research priority setting studies (13). This study has
followed this guidance to ensure the research priorities were
developed using a clear and transparent process using formal
consensus development methods. The study design, develop-
ment, and delivery was also informed by a systematic review
of research priority setting studies relevant to women’s health
(11). With 388 respondents from 40 countries participating in
the initial survey, 317 respondents from 43 countries partici-
pating in the interim prioritization survey, and 41 participants
from 11 countries included in the consensus development
meeting, the global participation achieved in this study
should secure the generalizability of the results within an in-
ternational context. The study included people with fertility184problems and they were able to suggest potential research un-
certainties during the initial survey, share their views
regarding the importance of research uncertainties during
the interim prioritization survey, and participate fully in the
consensus development meeting which prioritized the final
research priorities.
This consensus study is not without limitations. Consider-
ation should be given to the representativeness of the study’s
participants. For example, when considering the initial sur-
vey, there was a higher response from participants who iden-
tified as living in Europe (115 participants; 30%). To
participate in the initial survey and interim prioritization sur-
vey, English proficiency and literacy, a computer, and
internet access were required. We appreciate that limitations
in the representativeness of the sample could impact upon
the research uncertainties suggested and prioritized. There is
uncertainty regarding the optimal consensus development
method to prioritize research uncertainties, and methodolog-
ical research is required to evaluate different approaches to
priority setting and the use of different consensus methods.
Further contextual information, including the number of peo-
ple the research priority impacts upon, the feasibility of
answering the research priority, and the resources required
to address the research uncertainty could have assisted partic-
ipants to prioritize research uncertainties. Future methodo-
logical research should evaluate the use of contextual
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60 research uncertainties prioritised
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Prioritizing uncertainties
231 confirmed research uncertainties
 Male infertility: n=34
 Female and unexplained infertility: n=48
 Medically assisted reproduction: n=101
 Ethics, access, and organizationof care: n=48
Overview of the process of identifying research uncertainties.
Duffy. Priorities for future infertility research. Fertil Steril 2020.
Fertility and Sterility®Reflections on the Research Priorities
Reproductive medical care for men has lagged behind that for
women. Setting impactful and tractable priorities for male
reproduction is consequently a critically important task. For
diagnosis, the variation in morphology is extraordinary and
counting sperm is challenging, severely limiting our ability
to make predictions of male reproductive potential from the
standard semen analysis, and begging the question: are thereVOL. 115 NO. 1 / JANUARY 2021other, better tests of sperm? We need to explore how overall
health affects male fertility and whether treating other dis-
eases improves it. Because a man does not live in a vacuum,
we need to understand how the environment affects male
reproduction. When considering the treatment of male infer-
tility, men often ask what they can do to improve their
fertility, and well conducted studies into diet and nutraceuti-
cals are essential. The endocrine system drives the making of185
FIGURE 2
Top 10 research priorities for male infertility
1. Are sperm tests other than bulk parameters useful in evaluating male fertility? If so, 
which?
2. What is the emotional and psychological impact of male infertility? Can addressing 
it improve outcomes?
3. Do environmental factors cause male infertility? If so, which?
4. Does treating specific causes of male infertility improve outcomes?
5. Can we improve surgical sperm extraction outcomes by using endocrine 
stimulation protocols?
6. What modifiable risk factors cause male infertility?
7. Does treating modifiable risk factors improve outcomes?
8. What co-morbidities are associated with infertility?
9. Does treating co-morbidities improve outcomes?
10. Are nutraceuticals useful in improving male reproductive potential? If so, which?
Top 10 research priorities for female and unexplained infertility
1. Can age-related infertility be prevented?
2. Can a predictive model be developed, tested, and validated to compare the 
outcomes of different management strategies for couples with unexplained 
infertility?
3. In couples with unexplained infertility, what is the optimal ART?
4. Can a predictive model for fertility based upon ovarian reserve tests be developed, 
tested, and validated?
5. In women at risk of age-related infertility does standardized fertility assessment 
before attempting expectant management improve live birth rates?
6. What causes unexplained infertility?
7. In women with uterine fibroids what is the optimal management strategy to 
preserve fertility?
8. In women with otherwise unexplained infertility does hysteroscopic removal of an 
endometrial polyp increase live birth rates?
9. In women with mild intrauterine adhesions and otherwise unexplained infertility, 
does removal increase live birth rates?
10. In women with a uterine septum and otherwise unexplained infertility does 
hysteroscopic resection increase live birth rates?
Top 10 research priorities for medically assisted reproduction 
1. What are the causes of implantation failure?
2. What is the optimal treatment for women who are poor responders undergoing IVF
to increase live birth rates?
3. What is the optimal method of sperm selection in IVF cycles?
4. In couples with unexplained infertility does IUI increase live birth rates when 
compared with other ARTs, including IVF?
5. In couples with unexplained infertility what is the optimal number of IUI cycles 
before moving to IVF?
6. What is the optimal method of embryo selection in IVF cycles?
7. What are the factors which affect cycle to cycle variability in the number and 
quality of oocytes produced in an IVF cycle?
8. What is the optimal time interval between ovulation and IUI?
9. What is the emotional and psychological impact on children born using donor 
gametes?
10. What is the emotional and psychological impact of repeated fertility treatment 
failure?
Top 10 research priorities for ethics, access, and organization of care
1. Which public health interventions are effective in preventing infertility?
2. How can the cost of infertility treatment be reduced?
3. How can infertility treatment be made available in lower resource settings?
4. How should the information needs of people with infertility be met?
5. What age limit should be applied to women and men seeking infertility treatment?
6. What is the economic burden of infertility?
7. What is the minimum standard of care people with infertility should expect?
8. How should financial conflicts of interest be managed in clinical and research 
settings?
9. How should social egg freezing be regulated?
10. What are the optimal methods to report long term maternal and offspring outcomes 
across national and international settings?
The top 10 priorities for future infertility research in each of the four categories.
Duffy. Priorities for future infertility research. Fertil Steril 2020.
ORIGINAL ARTICLE: INFERTILITYsperm and further evidence is required to understand if hor-
monal therapy could improve the production of sperm and
improve live birth rates.
The priorities for unexplained infertility seek answers to
several challenging and long-standing questions, including
the prevention of age-related infertility and exploring the
role of fibroids, polyps, intrauterine adhesions, and uterine
septa in unexplained infertility. It is also surprising that it re-
mains unclear what the first line treatment is for couples with
unexplained infertility, IVF or IUI, and the timing of the supe-
rior treatment for that couple.
When considering medically assisted reproduction, new
large prospective cohorts that consider all variables and use
advance methodology will be required to addressed casual re-
lationships related to implantation failure. Similar complexity
will exist when studying oocyte yield and quality over subse-
quent IVF cycles, even though similar stimulation protocols
have been used. The three research priorities concerning the
effectiveness of IVF are seeking to identify optimal ovarian
stimulation protocols in poor responders, sperm selection
techniques, and embryo selection. These contrast with the
research priorities which explore if, when, and how IUI should
be used. To answer these effectiveness questions, well de-
signed randomized controlled trials will be required (26).
The psychological impact of fertility treatment is brought
into sharper focus with research priorities related to the
emotional and psychological impact of repeated fertility186treatment failure and in children following gamete donation.
Strong involvement of patient representatives, psychologists,
and behavioral scientists will be required to establish the
appropriate qualitative and quantitative studies to address
these important priorities.
The research priorities for ethics, access, and organization
of care broadly fall into two overarching themes: access and
infertility as a public health issue. When considering access,
cost is a major barrier to appropriate care, which is reflected
in the research priorities aiming to explore interventions to
reduce the cost of fertility treatment and increase the avail-
ability of fertility treatment in lower resources settings.
Turning to infertility as a public health issue, prevention of
infertility should be a key priority for public health initiatives.
We need to determine the minimum standard of care that peo-
ple with fertility problems should expect, especially if we are
seeking reimbursements for this care.Wider Context
A prioritized list of research uncertainties, developed to spe-
cifically highlight the most pressing clinical needs as
perceived by healthcare professionals, people with fertility
problems, and others, should help funding organizations
and researchers to set their future research agenda. The
selected list of research uncertainties should serve to focus a
discussion regarding the allocation of limited resources.VOL. 115 NO. 1 / JANUARY 2021
Fertility and Sterility®Many of the research priorities will require national and
international collaboration. Several countries, including
China, the Netherlands, UK, and the USA, have developed na-
tional networks to undertake infertility research (5). Further
development of national infrastructure is required. Collabora-
tion should spread beyond national boundaries and develop
within an international context. It is hoped the development
of a prioritized research agenda could be an important enabler
to deepen international collaboration. Development of
generic infrastructure could help foster collaboration,
including the use of minimum data sets, known as core
outcome sets, low cost data repositories, and standardized ap-
proaches to the reporting of research. A core outcome set has
recently been developed for future infertility trials (7). Over
400 healthcare professionals, researchers, and patients, from
40 countries, have used formal consensus development
methods to identify a core outcome set for infertility (9).
Consensus definitions have also been agreed for individual
core outcomes (10). It is hoped the core outcome set will pro-
vide generic tools to collect outcomes during research, pro-
vide concise guidance regarding statistical analysis, and
standardize the approach to research reporting (8).
Research priorities identified in this study correspond
with research priorities identified by the Priority Setting Part-
nership for Miscarriage, including determining the emotional
and psychological impact of miscarriage, investigating the
modifiable risk factors which cause miscarriage, and identi-
fying specific co-morbidities which cause miscarriage (24).
Other similarities exist when considering the research uncer-
tainties prioritized by the Priority Setting Partnership for
Endometriosis and International Polycystic Ovary Syndrome
Network (12).
Answering the prioritized research questions would
represent a significant step forward for our specialty. The
steering group recognizes the important role of research
which stems from the intellectual curiosity of individuals,
fundamental research which does not have an immediate
clinical application, and research which is funded by special
interest groups raising funding for the topic of their particular
interest. A blended research strategy should offer the optimal
pathway to improving clinical care and patient outcomes.
Perhaps the most important part of this process has been
the strengthening of relationships between partner organiza-
tions, health care professionals, and people with lived experi-
ence of infertility. The prioritized list of uncertainties that
require research should help funding organizations and re-
searchers to set their future research agenda. Our approach
should ensure that future research has the necessary reach
and relevance to inform clinical practice and to improve pa-
tient outcomes.APPENDIX. PRIORITY SETTING PARTNERSHIP
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ORIGINAL ARTICLE: INFERTILITYLas 10 principales prioridades para la investigacion de la infertilidad futura: un estudio de desarrollo de consenso internacional *
Pregunta de estudio: ¿Se pueden identificar las prioridades para la investigacion futura en infertilidad?
Respuesta resumida: fueron identificadas las 10 principales prioridades de investigacion para las cuatro areas de infertilidad mascu-
lina, infertilidad femenina e inexplicable, reproduccionmedicamente asistida, etica, acceso y organizacion de la atencion para personas
con problemas de fertilidad.
Lo que ya se sabe: quedan sin respuesta muchas preguntas fundamentales relacionadas con la prevencion, el manejo y las consecuen-
cias de la infertilidad.. Esta es una barrera para mejorar la atencion que reciben las personas con problemas de fertilidad.
Dise~no, tama~no y duracion del estudio: las posibles preguntas de investigacion se recopilaron a partir de una encuesta inicial internacio-
nal, una revision sistematica de guías de practica clínica y revisiones sistematicas Cochrane. Se priorizo una lista racionalizada de incerti-
dumbres de investigacion confirmadas en una encuesta internacional provisional. Las incertidumbres prioritarias de la investigacion se
discutieron durante una reunion dedesarrollo de consenso. Usando unmetodo de desarrollo de consenso formal, la tecnica de grupo nominal
modificado, diversas partes interesadas identificaron las 10 principales prioridades de investigacion para cada una de las categorías de in-
fertilidad masculina, infertilidad femenina e inexplicable, reproduccionmedicamente asistida y etica, acceso, y organizacion de la atencion.
Participantes / Materiales, entorno, metodos: profesionales de la salud, personas conproblemasde fertilidad yotros (financiadores de la
salud, proveedores de atencion medica, reguladores de la atencion medica, organismos de financiacion de la investigacion e investiga-
dores) se reunieron en un marco abierto y transparente utilizando metodos formales de consenso propugnados por James Lind Alliance.
Resultados principales y el papel del azar: La encuesta inicial fue completada por 388 participantes de 40 países, se enviaron 423
preguntas potenciales de investigacion. Catorce guías de practica clínica y 162 revisiones sistematicas Cochrane identificaron unas
236 posibles preguntas de investigacion.
Se ingreso una lista racionalizada de 231 incertidumbres de investigacion confirmadas en una encuesta de priorizacion provisional
completada por 317 encuestados de 43 países. Las 10 principales prioridades de investigacion para cada una de las cuatro categorías
de infertilidad masculina, Infertilidad femenina e inexplicable (incluida la infertilidad relacionada con la edad, quistes ovaricos, anom-
alías de la cavidad uterina y factor tubarico infertilidad), reproduccion medicamente asistida (incluida la estimulacion ovarica, IIU e
FIV), etica, acceso y organizacion de cuidado, se identificaron durante una reunion de desarrollo de consenso en la que participaron
41 participantes de 11 países. Estas prioridades de investigacion eran diversas y buscaban respuestas a preguntas sobre prevencion,
tratamiento y el impacto a largo plazo de la infertilidad.
Ellos destacaron la importancia de realizar investigaciones que a menudo se han pasado por alto, incluido el tratamiento de los aspectos
emocionales y impacto psicologico de la infertilidad, mejorando el acceso al tratamiento de fertilidad, particularmente en entornos de
menores recursos, y asegurando una regulacion apropiada. Abordar estas prioridades requerira diversas metodologías de investigacion,
incluidos aspectos cientificos de laboratorio, investigacion cualitativa y cuantitativa y aspectos cientificos poblacionales.
Limitaciones, motivos de precaucion: utilizamos metodos de desarrollo de consenso, que tienen limitaciones inherentes, incluyendo
la representatividad de la muestra de participantes, decisiones metodologicas informadas por juicio profesional y definiciones de con-
senso arbitrarias.
Implicaciones mas amplias de los hallazgos: Anticipamos que las prioridades de investigacion identificadas, desarrolladas para re-
saltar específicamente las mas urgentes percibidas por los profesionales sanitarios Las necesidades clínicas segun las, las personas con
problemas de fertilidad y otros, ayudaran a las organizaciones de financiacion de la investigacion e investigadores para desarrollar una
agenda futura de investigacion.
Financiamiento del estudio / Intereses en competencia: El estudio fue financiado por la Fundacion de InvestigacionMedica de Auck-
land, Catalyst Fund, Royal Sociedad de Nueva Zelanda y Maurice and Phyllis Paykel Trust. Geoffrey Adamson informa el patrocinio de
investigacion de Abbott, honorarios personales por parte de Abbott y LabCorp, un interes financiero en Advanced Reproductive Care,
membresía del comite del Comite de FIGO sobre Medicina Reproductiva, Comite Internacional para el Monitoreo de Tecnologías de Re-
produccion Asistida, Federacion Internacional de Fertility Societies y World Endometriosis Research Foundation, y patrocinio de inves-
tigacion del Comite Internacional de Monitoreo de Tecnologías de reproduccion asistida de Abbott y Ferring. Siladitya Bhattacharya
informa que es el editor en jefe de Human Reproduction Open y editor del Grupo Cochrane de Ginecología y Fertilidad. Hans Evers in-
forma ser el editor emerito de Human Reproduction. Andrew Horne informa el patrocinio de investigacion de la Chief Scientist’s office,
Ferring, Consejo investigacion medica, Instituto Nacional de Investigaciones en Salud, y Bienestar de las mujeres y honorarios de con-
sultoría de Abbvie, Ferring, Nordic Pharma y Roche Diagnostics. M. Louise Hull informa subvenciones de Merck, subvenciones de My-
ovant, subvenciones de Bayer, fuera del presente trabajo y propiedad en Embrace Fertility, una empresa privada de fertilidad. Neil
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